Alvotech Ordinary Shares (ALVO) Stock
Key stats
- Market cap
- $1.76B
- Price / Earnings ratio
- -9.7x
- EPS (TTM)
- -$0.62
- Volume
- Loading
- 52-week high
- $6.53
- 52-week low
- $2.94
Source: third-party data provider, as of November 13, 2026
Compare with ALVO
Recent news

New Strong Sell Stocks for October 21st
New Strong Sell Stocks for October 21st
ALVO

ALVO Stock Jumps On Double Upgrade — Why Barclays Sees A 59% Upside
ALVO Stock Jumps On Double Upgrade — Why Barclays Sees A 59% Upside
ALVO

Alvotech Q2 Earnings Call Highlights
Alvotech Q2 Earnings Call Highlights
ALVO

Alvotech (ALVO) Reports Q2 Loss, Beats Revenue Estimates
Alvotech (ALVO) Reports Q2 Loss, Beats Revenue Estimates
ALVO
News tone: automated (AI) classification of the article's content, not a price prediction.
Technical indicators
- RSI 14
- 49.43
- MACD 12/26/9
- -0.14
- EMA 9 of MACD
- -0.17
- MACD histogram
- 0.03
- SMA 50
- $5.27
- Price below SMA 50
- EMA 50
- $4.95
- Price below EMA 50
- SMA 200
- $4.19
- Price above SMA 200
- EMA 200
- $4.58
- Price above EMA 200
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst ratings
Analyst consensus: Buy
Based on 4 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
Financials
Performance
Debt & Balance Sheet
Revenue to Profit
2025Earnings
No data available
Source: third-party data provider
Latest news

New Strong Sell Stocks for October 21st
New Strong Sell Stocks for October 21st
ALVO

ALVO Stock Jumps On Double Upgrade — Why Barclays Sees A 59% Upside
ALVO Stock Jumps On Double Upgrade — Why Barclays Sees A 59% Upside
ALVO

Alvotech Q2 Earnings Call Highlights
Alvotech Q2 Earnings Call Highlights
ALVO

Alvotech (ALVO) Reports Q2 Loss, Beats Revenue Estimates
Alvotech (ALVO) Reports Q2 Loss, Beats Revenue Estimates
ALVO

Alvotech Hits Critical Inflection as Biosimilar Pipeline Nears FDA Decisions
Alvotech Hits Critical Inflection as Biosimilar Pipeline Nears FDA Decisions
ALVO

ALVO Stock Gains 19% on FDA Resubmission of Biosimilar BLAs
ALVO Stock Gains 19% on FDA Resubmission of Biosimilar BLAs
ALVO

Alvotech Nears Inflection Point With 5 U.S. Biosimilars Targeted by Year-End
Alvotech Nears Inflection Point With 5 U.S. Biosimilars Targeted by Year-End
ALVO

Alvotech Plans June FDA Resubmissions, Sees Biosimilar Approvals by Year-End
Alvotech Plans June FDA Resubmissions, Sees Biosimilar Approvals by Year-End
ALVO

Alvotech (ALVO) Reports Q1 Loss, Lags Revenue Estimates
Alvotech (ALVO) Reports Q1 Loss, Lags Revenue Estimates
ALVO

ALVO Investigation: Investors Encouraged to Contact Kirby McInerney LLP
ALVO Investigation: Investors Encouraged to Contact Kirby McInerney LLP
ALVO
News tone: automated (AI) classification of the article's content, not a price prediction.
About Alvotech Ordinary Shares
No description available.
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Ms. Lisa Graver | Chief Executive Officer | 1972 |
| Mr. Vilhelm Robert Wessman | Founder & Executive Chairman | 1969 |
| Ms. Linda Jonsdottir | Chief Financial Officer | 1978 |
| Mr. Joseph E. McClellan | Chief Operating Officer | 1974 |
| Ms. Neha Patel | Chief Information Officer | — |
| Mr. Benedikt Stefansson | Vice President of Investor Relations & Global Communications | — |
| Ms. Sarah Macleod | Head of Global Communications | — |
| Ms. Kathryn Gunnarsson | Senior Vice President of Global Talent & People Experience | — |
| Mr. Anthony M. Maffia III | Chief Quality & Regulatory Officer | — |
| Dr. Balaji Venkataramanan Prasad M.D. | Chief Strategy Officer | — |
Fundamentals
Valuation
Profitability
Trading
Source: third-party data provider, as of November 13, 2026
Technical indicators
- RSI 14
- 49.43
- MACD 12/26/9
- -0.14
- EMA 9 of MACD
- -0.17
- MACD histogram
- 0.03
- SMA 50
- $5.27
- Price below SMA 50
- EMA 50
- $4.95
- Price below EMA 50
- SMA 200
- $4.19
- Price above SMA 200
- EMA 200
- $4.58
- Price above EMA 200
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst views
4 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
- Low
- $7.00
- Average
- $8.00
- High
- $9.00
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2022 | -26.6 | -16.8 | +16.1 | -12.3 | -7.5 | +0.3 | +62.6 | |||||
| 2023 | +19.9 | +13.5 | -7.3 | -25.0 | -16.0 | -9.2 | +16.3 | +3.4 | -8.2 | -1.4 | +10.6 | +21.5 |
| 2024 | +38.6 | -3.5 | -22.5 | +16.3 | -4.1 | -12.9 | -5.3 | +1.0 | +4.8 | +8.6 | -9.8 | +13.5 |
| 2025 | -3.3 | -8.2 | -12.9 | -18.7 | +44.1 | -18.7 | -0.1 | -8.2 | +3.0 | -6.6 | +1.4 | +6.0 |
| 2026 | +7.4 | -25.0 | -13.4 | -7.7 | -2.9 | +14.6 | +15.1 | +36.9 | +10.7 | -17.3 | +9.8 |



